Investigations into two novel nutraceutical nootropic interventions, PCSO-524® and CDRI 08®, on the behaviour, cognition, mood, and neurophysiology of children and adolescents with clinical and subclinical levels of Attention-Deficit/Hyperactivity Disorder (ADHD)

Childhood attention-deficit/hyperactivity disorder (ADHD) has a prevalence rate of 3.4% worldwide, with subclinical levels of associated symptoms estimated to be upwards of 23%. This thesis explored the effects of two novel alternative interventions on the behaviour, cognition, mood, and neurophysiology of children and adolescents exhibiting clinical and subclinical levels of ADHD. Improvements were reported in cognitive outcomes, neurophysiology, and parent-reported behaviour. This work provides an original insight into the field of subclinical ADHD symptoms, and the safe and efficacious use of alternative treatments in a vulnerable population.